Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines

  • Authors:
    • Karine Serhal
    • Claude Baillou
    • Nicolae Ghinea
    • Philippe Fontanges
    • Franck P. Dupuy
    • François M. Lemoine
    • Roger Lacave
  • View Affiliations

  • Published online on: December 1, 2007     https://doi.org/10.3892/ijo.31.6.1357
  • Pages: 1357-1365
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Many strategies have been proposed to circumvent cancer development or prevent its growth. One of the promising strategies is to direct the immune response toward tumour antigens. This can be achieved by loading dendritic cells, the most potent antigen presenting cells, with tumour antigens. Fusion of dendritic cells (DC) with tumour cells is an attractive way to load the DC with all tumour antigens regardless of their immunogenicity status and the fact that they have, or not, been identified. The aim of our study was to characterise the immunophenotype of fused cells, monitor the evolution of the fusion interface and the distribution of surface antigens over time and assess for their maturation status and functionality in vitro. We used polyethylene glycol to fuse DC with Her2/neu positive breast cancer cell line T-47D. We demonstrate that false positive events accounted in flow cytometry can be identified using confocal microscopy to avoid an overestimation of fusion efficiency and to distinguish clearly hybrid cells from aggregated or phagocytosed cells. We used imaging means to demonstrate the conservation of presentation molecules (MHC II, CD1a), co-stimulatory molecules (CD40, CD80, CD86), as well as tumour antigens (Her2/neu, cytokeratins) in optimised conditions. Fused cells were only recognisable for 48 h as assessed by membrane staining and membranous antigen distribution. Fusion was necessary for their maturation to be accompanied by functional activity such as secretion of cytokines and perforin. These results suggest that hybrid cells generated by the fusion of DC and tumour cells can be easily identified and characterised using imaging techniques, and that, regarding functionality and cytokine secretion, they appear to be good candidates for anti-tumour therapies namely in breast cancer.

Related Articles

Journal Cover

December 2007
Volume 31 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Serhal K, Baillou C, Ghinea N, Fontanges P, Dupuy FP, Lemoine FM and Lacave R: Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines. Int J Oncol 31: 1357-1365, 2007
APA
Serhal, K., Baillou, C., Ghinea, N., Fontanges, P., Dupuy, F.P., Lemoine, F.M., & Lacave, R. (2007). Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines. International Journal of Oncology, 31, 1357-1365. https://doi.org/10.3892/ijo.31.6.1357
MLA
Serhal, K., Baillou, C., Ghinea, N., Fontanges, P., Dupuy, F. P., Lemoine, F. M., Lacave, R."Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines". International Journal of Oncology 31.6 (2007): 1357-1365.
Chicago
Serhal, K., Baillou, C., Ghinea, N., Fontanges, P., Dupuy, F. P., Lemoine, F. M., Lacave, R."Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines". International Journal of Oncology 31, no. 6 (2007): 1357-1365. https://doi.org/10.3892/ijo.31.6.1357